Results 71 to 80 of about 46,090 (276)

Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis

Advanced Science, EarlyView.
FAK signaling drives chemoresistance and tumor evolution in pancreatic ductal adenocarcinoma. The FAK inhibitor IN10018 restores gemcitabine sensitivity by inducing SLC7A11‐mediated ferroptosis through the PI3K‐Akt pathway and remodeling the tumor microenvironment, reducing mesenchymal components while enhancing CD8+ T‐cell infiltration in preclinical ...
Yingjin Wang, Hui Yang, Baoyuan Zhang, Yongsu Ma, Kuangen Zhang, Peng Wang, Jiapeng Yang, Zaiqi Wang, Rong Liu, Xiaodong Tian, Ning Zhang, Yinmo Yang   +11 more
wiley   +1 more source

Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo

Advanced Science, EarlyView.
Dual priming with minocycline and photodynamic priming reprograms the pancreatic tumor microenvironment to overcome chemoresistance. By suppressing DNA repair enzyme Tdp1, inducing photooxidative damage, and enhancing irinotecan delivery via light‐activated nanoencapsulation, this strategy remodels the tumor microenvironment and drives immune ...
Fernanda V. Cabral, Jose Quilez‐Alburquerque, Olivia Mooradian, Shivendran Vytheswarran, Badri Parshad, Girgis Obaid, Huang‐Chiao Huang, Tayyaba Hasan   +7 more
wiley   +1 more source

Elevated PAF1-RAD52 axis confers chemoresistance to human cancers

Cell Reports, 2023
Summary: Cisplatin- and gemcitabine-based chemotherapeutics represent a mainstay of cancer therapy for most solid tumors; however, resistance limits their curative potential.
Sanchita Rauth, Koelina Ganguly, Pranita Atri, Seema Parte, Rama Krishna Nimmakayala, Venkatesh Varadharaj, Palanisamy Nallasamy, Raghupathy Vengoji, Ayoola O. Ogunleye, Imayavaramban Lakshmanan, Ramakanth Chirravuri, Mika Bessho, Jesse L. Cox, Jason M. Foster, Geoffrey A. Talmon, Tadayoshi Bessho, Apar Kishor Ganti, Surinder K. Batra, Moorthy P. Ponnusamy   +18 more
doaj   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Advanced Science
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a dismal prognosis. Gemcitabine‐based chemotherapy has emerged as a first‐line treatment for PDAC.
Ying‐Qin Zhu, Yue Huang, Yin‐Hao Shi, Chen‐Song Huang, Guang‐Yin Zhao, Zhi‐De Liu, Ming‐Jian Ma, Jing‐Yuan Ye, Xiang Xu, Qi Liu, Xi‐Tai Huang, Jie‐Qin Wang, Qiong‐Cong Xu, Xiao‐Yu Yin   +13 more
doaj   +1 more source

DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC

Advanced Science, EarlyView.
This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian, Shihang Pu, Zhipeng Xu, Yiheng Ding, Ling Jin, Baochao Li, Qi Li, Xiaohai Xi, Zengjun Wang, Jiajun Xing, Aiming Xu   +10 more
wiley   +1 more source

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Wang, X, Jing Chen, Fan Yan, Xin, W, He Ren, Yan, F, Qian, D, Li, J, Hao, J, Wen Xin, Dong Qian, Chongbiao Huang, Jia, L, Song Gao, Jing Li, Chen, J, Huang, C, Zhao, T, Ren, H, Gao, S, Li Jia, Jihui Hao, Tiansuo Zhao, Xiuchao Wang   +23 more
core   +1 more source

FOXO3a/miR-4259-driven LDHA expression as a key mechanism of gemcitabine sensitivity in pancreatic ductal adenocarcinoma

Cancer & Metabolism
Background Lactate dehydrogenase A (LDHA) can regulate tumorigenesis and cancer progression. Nevertheless, whether the regulation of LDHA is involved in the development of gemcitabine resistance in PDAC has not yet been fully elucidated.
Tung-Wei Hsu, Wan-Yu Wang, Hsin-An Chen, Tzu-Hsuan Wang, Chih-Ming Su, Po-Hsiang Liao, Alvin Chen, Kuei-Yen Tsai, George Kokotos, Cheng-Chin Kuo, Ching-Feng Chiu, Yen-Hao Su   +11 more
doaj   +1 more source

Clinical application and drug resistance mechanism of gemcitabine

Frontiers in Cell and Developmental Biology
Gemcitabine, as a nucleoside analog, exerts a broad-spectrum antitumor effect by interfering with DNA synthesis, but its clinical application is limited by drug resistance. The drug resistance mechanism involves metabolic abnormalities (such as downregulation of deoxycytidine kinase (dCK), nucleoside transporter hENT1 deficiency), enhanced DNA repair ...
Zhang, Xuanrui, Qi, Bing, Chen, Jing
openaire   +2 more sources

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source